Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN100 for prevention of Staphylococcus aureus pneumonia in heavily colonized mechanically ventilated subjects
2016-002146-23Phase 2Terminated
- Sponsor
- Arsanis
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in staphylococcal pneumonia comparing ASN100 with Placebo (2 arms). Primary endpoint: Proportion of subjects developing Staphylococcus aureus pneumonia. Started Dec 2016; status: terminated.
02
Drugs
ASN100
03
Conditions
staphylococcal pneumonia
Beyond the preview
Go deeper on 2016-002146-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002146-23.